Neuraxpharm pursues growth strategy for business in Switzerland
The leading European central nervous system specialty company expands its operations in the highly attractive Swiss market and introduces Jörg Gärtner as new country manager
Dusseldorf and Liestal, May 3, 2022 – Neuraxpharm Group (Neuraxpharm) ignites the next level of their business in Switzerland to leverage the full potential of the important pharmaceutical market. After having laid the groundwork for its Swiss business in the recent past, Neuraxpharm reinforces its commitment to the market with today’s appointment of Jörg Gärtner as Country Manager for Switzerland. As experienced executive, Jörg Gärtner will focus on advancing Neuraxpharm as central nervous system (CNS) specialist in the Swiss market.
